Abstract
Advanced Glycation Endproducts (AGEs) are a group of heterogeneous compounds formed by the non enzymatic reactions between aldehydic group of reducing sugars with proteins, lipids or nucleic acids. Formation and accumulation of AGEs are related with the aging process and are accelerated in diabetes. Type 2 diabetes are the most common form of diabetes, which are characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta cell function and mass. The pathogenic role of AGEs in vascular diabetic complications is widely recognised. Recently, other aspects of the detrimental effects of AGEs in type 2 diabetes have emerged: AGEs interfere with the complex molecular pathway of insulin signalling, leading to insulin resistance; AGEs modify the insulin molecule, and consequently, its function; AGEs decrease insulin secretion and insulin content. In this article, we review the role of AGEs in type 2 diabetes, beyond their involvement in vascular complications.
Keywords: Diabetes, advanced glycation end products, pancreatic β-cells, insulin resistance, metabolic syndrome, hyperglycemia, glucose homeostasis, methylglyoxal, glycolaldehyde, AGE pentosidine, phosphorylation, musculoskeletal tissues
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications
Volume: 11 Issue: 2
Author(s): Alessandra Puddu and Giorgio L. Viviani
Affiliation:
Keywords: Diabetes, advanced glycation end products, pancreatic β-cells, insulin resistance, metabolic syndrome, hyperglycemia, glucose homeostasis, methylglyoxal, glycolaldehyde, AGE pentosidine, phosphorylation, musculoskeletal tissues
Abstract: Advanced Glycation Endproducts (AGEs) are a group of heterogeneous compounds formed by the non enzymatic reactions between aldehydic group of reducing sugars with proteins, lipids or nucleic acids. Formation and accumulation of AGEs are related with the aging process and are accelerated in diabetes. Type 2 diabetes are the most common form of diabetes, which are characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta cell function and mass. The pathogenic role of AGEs in vascular diabetic complications is widely recognised. Recently, other aspects of the detrimental effects of AGEs in type 2 diabetes have emerged: AGEs interfere with the complex molecular pathway of insulin signalling, leading to insulin resistance; AGEs modify the insulin molecule, and consequently, its function; AGEs decrease insulin secretion and insulin content. In this article, we review the role of AGEs in type 2 diabetes, beyond their involvement in vascular complications.
Export Options
About this article
Cite this article as:
Puddu Alessandra and L. Viviani Giorgio, Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564115
DOI https://dx.doi.org/10.2174/187153011795564115 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins and Ion Channels. Functional Interactions and Therapeutic Consequences
Current Pharmaceutical Biotechnology Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design The Contribution of Nitric Oxide and Carbon Monoxide to Neuronal Function and Development
Central Nervous System Agents in Medicinal Chemistry Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews Density Functional Theory Study of Antioxidant Adsorption onto Single- Wall Boron Nitride Nanotubes: Design of New Antioxidant Delivery Systems
Combinatorial Chemistry & High Throughput Screening The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies
Combinatorial Chemistry & High Throughput Screening Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology <i>In-silico</i> Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry The Interaction of DNA-Binding Ligands with Trinucleotide-Repeat DNA: Implications for Therapy and Diagnosis of Neurological Disorders
Current Topics in Medicinal Chemistry Genome-Scale Technologies Foster Advances in Neurological and Behavioral Research
Current Psychiatry Reviews Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”?
Current Vascular Pharmacology Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry